Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
A549 Cells
Administration, Inhalation
Amodiaquine
/ chemistry
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Drug Compounding
Drug Repositioning
Drug Stability
Human Umbilical Vein Endothelial Cells
Humans
Lung Neoplasms
/ drug therapy
Nanoparticles
Particle Size
Spheroids, Cellular
/ cytology
3D spheroid
Amodiaquine
Autophagy
Design of experiments
Drug repurposing
High pressure homogenization
Non-small cell lung cancer
Scale-up
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
03
12
2019
revised:
24
05
2020
accepted:
28
05
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
30
3
2021
Statut:
ppublish
Résumé
New drug and dosage form development faces significant challenges, especially in oncology, due to longer development cycle and associated scale-up complexities. Repurposing of existing drugs with potential anti-cancer activity into new therapeutic regimens provides a feasible alternative. In this project, amodiaquine (AQ), an anti-malarial drug, has been explored for its anti-cancer efficacy through formulating inhalable nanoparticulate systems using high-pressure homogenization (HPH) with scale-up feasibility and high reproducibility. A 3
Identifiants
pubmed: 32600728
pii: S0928-4931(19)34521-7
doi: 10.1016/j.msec.2020.111139
pii:
doi:
Substances chimiques
Amodiaquine
220236ED28
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111139Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest.